Literature DB >> 16606887

Macular telangiectasia: a simplified classification.

Emily Chew, Mark Gillies, Alan Bird.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16606887     DOI： 10.1001/archopht.124.4.573

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  7 in total

1.  Resveratrol inhibits pathologic retinal neovascularization in Vldlr(-/-) mice.

Authors:  Jing Hua; Karen I Guerin; Jing Chen; Shaday Michán; Andreas Stahl; Nathan M Krah; Molly R Seaward; Roberta J Dennison; Aimee M Juan; Colman J Hatton; Przemyslaw Sapieha; David A Sinclair; Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-25       Impact factor: 4.799

2.  The prevalence of macular telangiectasia type 2 in the Beaver Dam eye study.

Authors:  Ronald Klein; Barbara A Blodi; Stacy M Meuer; Chelsea E Myers; Emily Y Chew; Barbara E K Klein
Journal:  Am J Ophthalmol       Date:  2010-07       Impact factor: 5.258

3.  Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress.

Authors:  Michael I Dorrell; Edith Aguilar; Ruth Jacobson; Oscar Yanes; Ray Gariano; John Heckenlively; Eyal Banin; G Anthony Ramirez; Mehdi Gasmi; Alan Bird; Gary Siuzdak; Martin Friedlander
Journal:  J Clin Invest       Date:  2009-02-02       Impact factor: 14.808

4.  Endothelial SRF/MRTF ablation causes vascular disease phenotypes in murine retinae.

Authors:  Christine Weinl; Heidemarie Riehle; Dongjeong Park; Christine Stritt; Susanne Beck; Gesine Huber; Hartwig Wolburg; Eric N Olson; Mathias W Seeliger; Ralf H Adams; Alfred Nordheim
Journal:  J Clin Invest       Date:  2013-04-08       Impact factor: 14.808

5.  Analysis of candidate genes for macular telangiectasia type 2.

Authors:  Nancy L Parmalee; Carl Schubert; Joanna E Merriam; Kaija Allikmets; Alan C Bird; Mark C Gillies; Tunde Peto; Maria Figueroa; Martin Friedlander; Marcus Fruttiger; John Greenwood; Stephen E Moss; Lois E H Smith; Carmel Toomes; Chris F Inglehearn; Rando Allikmets
Journal:  Mol Vis       Date:  2010-12-14       Impact factor: 2.711

6.  Identification of a potential susceptibility locus for macular telangiectasia type 2.

Authors:  Nancy L Parmalee; Carl Schubert; Maria Figueroa; Alan C Bird; Tunde Peto; Mark C Gillies; Paul S Bernstein; Krzysztof Kiryluk; Joseph D Terwilliger; Rando Allikmets
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.752

Review 7.  When is macular edema not macular edema? An update on macular telangiectasia type 2.

Authors:  Lihteh Wu
Journal:  Taiwan J Ophthalmol       Date:  2015-11-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.